Our commitment is to help you understand your place on this spectrum so you can make informed decisions.
UroPartners is not just a medical practice; we're the largest urology group in the Midwest and among the biggest nationwide. This scale translates directly into unmatched experience in prostate cancer treatment. Our active registry includes 16,000 prostate cancer patients, giving us a distinct advantage in navigating the complexities of this disease. From early detection to managing advanced metastatic cases, our collective experience spans all phases of cancer care.
We leverage the country's most advanced data and analytical software for our prostate cancer registry. Our dedicated data team actively manages this information, ensuring each patient receives the most appropriate, up-to-date treatment precisely when it's needed – in real time, without the wait between appointments.
At UroPartners Prostate Centers, your well-being is our focus. We combine extensive experience and training with cutting-edge technology to deliver personalized, compassionate care that meets nationally recognized best practices..
Starting with your initial consultation and throughout your treatment we partner with you every step of the way. Because technology is constantly improving, we believe it is our duty to continually educate and implement methods and techniques that provide our patients with the highest and quality of care. Our team of board-certified urologists and radiation oncologist work seamlessly to personalize your care and treatment plan.
SpaceOAR System - Rectal Protection for Prostate Cancer Radiation Therapy Patients
UroPartners is now offering a new tool that is proven to protect prostate cancer patients from the negative effects of radiation therapy.
Welcome to the UroPartners Prostate Cancer Treatment Center in Glenview—a specialized care hub dedicated to providing advanced, compassionate, and highly personalized prostate cancer care to patients across the North Shore and Chicagoland communities. Located at 2600 Patriot Blvd (Unit J) in the heart of The Glen, our state-of-the-art facility brings together board-certified urologists and radiation oncologists under one roof. By combining cutting-edge diagnostic technology with innovative radiation therapies—including Intensity-Modulated Radiation Therapy (IMRT), Image-Guided Radiation Therapy (IGRT), and radiopharmaceuticals—we ensure every patient receives an accurate diagnosis and a tailored treatment plan designed to maximize outcomes while preserving quality of life. At UroPartners Glenview, we understand that a prostate cancer diagnosis can feel overwhelming. Our multidisciplinary team is committed to guiding you and your family through every stage of your journey—from initial screening and advanced imaging to precision.
Parthiv Mehta, MD – Radiation Oncologist
Par Mehta, M.D. is a Board Certified Radiation Oncologist specializing in the treatment of prostate cancer. He possesses expertise and advanced training in intensity-modulated radiation therapy (IMRT), image-guided radiation therapy (IGRT), and prostate brachytherapy. Additionally, he is an expert in utilizing The Calypso® 4D Localization System (GPS for the body).
After earning his bachelor’s degree in engineering from the University of Michigan. Dr. Mehta entered the Medical Scholars Program at the University of Illinois where he completed an M.D as well as an M.B.A degree. He completed his residency in radiation oncology at Rush University Medical Center and entered into a brachytherapy fellowship program at Beth Israel Medical Center in New York City. During this time he completed research which has been published in several clinical journals.
Dr. Mehta is a member of the American Society for Therapeutic Radiology and Oncology, the American Society of Clinical Oncology, the American Medical Association, the Radiological Society of North America, the American College of Radiation Oncology, and the American Brachytherapy Society.
Dr. Mehta is not only committed to providing his patients with the highest quality cutting edge treatment options, he also ensures they are thoroughly informed about their treatment choices.
Ramji Rajendran, MD, PhD – Radiation Oncologist
Dr. Ramji Rajendran is a board‑certified radiation oncologist who provides advanced, evidence‑based radiation therapy for patients with cancer, with particular expertise in genitourinary malignancies, including prostate, bladder, and testicular cancer. He is committed to delivering precise, personalized treatment while supporting patients and their families throughout every stage of care.
Dr. Rajendran earned both his MD and PhD from the University of Illinois at Urbana‑Champaign, following undergraduate studies at the University of Virginia. He completed his internship at Penn Presbyterian Medical Center and his radiation oncology residency at the Hospital of the University of Pennsylvania in Philadelphia, where he received comprehensive training at a nationally recognized academic medical center. He is board certified by the American Board of Radiology in Radiation Oncology.
Dr. Rajendran has an extensive research background, with published work and national and international presentations focusing on prostate organ motion, proton radiation therapy, and radiation treatment of thoracic and breast cancers. He has a strong interest in cancer survivorship and believes in empowering patients and caregivers through education, communication, and shared decision‑making.
Yashbir Mehta, M.D. - Radiation Oncologist
After finishing medical school from the University of Panjab, I came to Vancouver, Canada where I finished my internship at the University of British Columbia, followed by 2 years of Internal Medicine residency at the University of Ottawa, Canada.
I started my general radiology training at Cook County Hospital in Chicago and finished my radiation oncology training at Rush Medical College. I became an attending in radiation oncology at Rush Medical College followed by 7 years as attending staff at Lutheran General Hospital in Park Ridge, IL, in the department of radiation oncology. I was appointed director of radiation oncology at Weiss Memorial Hospital in Chicago for 7 years.
In 1983 I opened my own freestanding radiation oncology center in Waukegan, the first in the state of Illinois. In 199a I opened another freestanding radiation oncology center at Condell Medical Center in Libertyville, IL and in 2003, after closing my Waukegan radiation center, I opened a brand new, state of the art facility in Gurnee, IL, where I still continue working and as of September 2019, with UroPartners.
I am board certified in radiology and radiation oncology. I specialize not only in treating prostate cancer, but also other cancers like breast cancer, lung cancer, and head & neck cancers.
I have taken special training in brachytherapy in Seattle for prostate cancer and for head & neck cancers. I specialize in IMRT, IGRT, and stereotactic radiation.
We also opened a gamma knife center in Gurnee in collaboration with our neurosurgeon, Dr. Tomas Helenoski.
I love the field of radiation oncology and it gives me great pleasure to take care of cancer patients and their families. The field of radiation oncology is very satisfying for me, so much so, that my son, Neil Mehta, M.D., has followed in my footsteps to become a radiation oncologist. He is also working with UroPartners and with the Cancer Treatment Centers of America.
In my spare time I enjoy golfing, traveling with my wife, and reading.
Parvathy Kurup, M.D. – Radiation Oncologist
Dr. Parvarthy Kurup is board-certified in therapeutic radiology and a fellow of the American College of Radiation Oncology. She is also a member of the American College of Radiation Oncology and the American Society of Therapeutic Radiology and Oncology. She received her medical degree and completed an internship at Madras University, JIPMER Hospital in Pondicherry, India. Dr. Kurup completed her residency in therapeutic radiology at Rush Presbyterian St. Luke's Medical Center in Chicago, IL. She then worked at Neutron Therapy Center at Fermi Lab in Bavaria, IL for three years as a radiation oncologist and researcher. During that period she was a tutor at Rush Medical Center. Dr. Kurup has treated cancer patients with external beam, intracavitary, interstitial and stereotactic radiation in the past. More than anything, Dr. Kurup goes out of her way to reduce the fear and anxiety that comes with cancer through education and care.
Your Treatment Plan
Following your consultation the radiation oncologist will work with the rest of the team to design your personalized treatment plan. To ensure accurate targeting of disease:
-You will undergo a treatment planning CT scan
-Your team will collaborate to identify the specific treatment area, sparing healthy tissue
Your radiation therapists are experts at positioning patients to ensure accurate delivery of the radiation throughout your treatments. Our radiation therapists are committed to making treatments a warm and pleasant experience.
Our Prostate Centers of Excellence offer innovative modalities and technologies in order to ensure the best treatment outcomes possible. We are committed to doing everything we can during your battle with prostate cancer.
Our services include:
Calypso is used in conjunction with IMRT to ensure that the highly tailored treatment created by your medical team is delivered exactly where it is intended with millimeter precision. Prior to initiating the radiation treatments your physician will implant small fiducial markers (transponders) into your prostate or prostatic bed. These tiny beacons transmit a signal that is picked up by the Calypso system allowing for real time tracking of your prostate. If during treatment your prostate moves out of the intended treatment area the radiation therapists will stop your treatment and realign you ensuring that the radiation is delivered to the intended target.
Monitoring prostate organ motion during radiation therapy delivery allows for increased clinical confidence that comes with knowing the tumor target is accurately and precisely aligned with the delivery of the radiation beam during every patient treatment.
SpaceOAR® System – Rectal Protection for Prostate Cancer Radiation Therapy Patients
UroPartners is now offering a new tool that is proven to protect prostate cancer patients from the negative effects of radiation therapy.
Because of the close proximity of the prostate to the rectum, prostate radiation therapy typically results in some radiation hitting the rectum, which can sometimes cause side effects, such as pain during bowel movements, rectal urgency, bleeding or loose stools during or after radiation treatment. That’s why the rectum is called the Organ At Risk (OAR) during prostate radiation therapy.
SpaceOAR System reduces rectal injury in men receiving prostate cancer radiation therapy by acting as a spacer – pushing the rectum away from the prostate and out of the high dose radiation region.
The hydrogel spacer is injected during a minimally invasive procedure, and — once in place — patients typically can’t feel it. The hydrogel is safe and similar to other products used in brain surgery, cardiology and ophthalmology. It remains in place for 3 months during radiation treatment, and is then absorbed and leaves the body in the patient’s urine — leaving nothing behind.
SpaceOAR System has been has been clinically proven and studied in a US Clinical Trial and is FDA cleared for sale in the US.
To learn more about SpaceOAR hydrogel please see the Frequently Asked Questions (FAQ) Patient Guide
For more information on SpaceOAR system go to http://www.spaceoar.com
Please see Instructions for Use for a complete list of potential risks, warnings and precautions.
What You Should Know Before Starting Treatment
Men facing a prostate cancer diagnosis often face the challenge of navigating the multitude of treatment options available to determine the right path for them. Each year, about 290,000 men are diagnosed with prostate cancer in the United States. It is the second most common cancer among U.S. men, occurring in one in eight males.
A variety of treatment options are available for prostate cancer based on prognosis. To determine which treatment is best for them, patients should work together with their doctor to weigh the advantages and disadvantages of all appropriate options. Radiation treatment, also known as radiotherapy, is the most effective form of treatment for many men with prostate cancer. Recent innovations and advanced technologies, make radiation an even stronger cornerstone of treatment. While radiation therapy often leads to successful patient outcomes, it is important to protect surrounding healthy tissue from radiation exposure. Damage to this healthy tissue can result in long-term side effects, which can impact patients’ quality of life.
Recognizing the need to offer the latest advancements in radiotherapy and best patient outcomes, prostate cancer specialists from UroPartners, are among the first in the Chicago area to use Barrigel®, an advanced technology that protects healthy tissue from radiation exposure. Barrigel is an injectable biodegradable gel that is injected between the prostate and the rectum to create therapeutic distance between the two organs, lowering the risk of toxicity to the rectum and, if desired, the seminal vesicles which produce fluid that becomes part of the semen. This technique minimizes potential unwanted side effects and complications of prostate radiotherapy.2 In the first FDA clinical study of a rectal spacer using a shortened course of radiotherapy (hypofractionated radiotherapy) 98.5% of patients showed Barrigel to be effective in achieving a significant reduction in radiation to the rectum.
This reduced unwanted side effects, including inflammation of the rectum (radiation proctitis), diarrhea, and hemorrhoids. Barrigel is made from Non-Animal Stabilized Hyaluronic Acid (NASHA®), which has been proven safe and effective, and has been used for more than 20 years in over 50 million medical procedures in men, women and children worldwide.3 A groundbreaking spacing technology, Barrigel addresses the limitations of current spacing materials by offering patient-specific customization with the ability to sculpt the spacer for personalized coverage. The result is more efficient, patient tailored results for optimal coverage.
.
